Novartis expect to develop 14 new blockbuster drugs by 2017

As reported by Reuters, the swiss pharmaceutical company, Novartis have reported that they expect to develop fourteen or more blockbuster drugs by 2017.

Novartis has announced that it has 139 projects in clinical development including over 73 new molecular entities spread across a variety of diseases. The swiss pharma company have stated that their most promising of drugs are those used to treat heart failure, psoriasis and multiple sclerosis.

 

Are you looking for a role in the pharmaceutical industry in Switzerland?

Click here to search our pharmaceutical jobs in Switzerland now >

 

Novartis expects to develop 14 new blockbuster drugs by 2017Novartis expects to develop 14 new blockbuster drugs by 2017Novartis expects to develop 14 new blockbuster drugs by 2017Novartis expects to develop 14 new blockbuster drugs by 2017

Posted in: Industry News, News
CK Logo in place of featured image